Checkpoint inhibition for early-stage hormone receptor-positive breast cancer

Introduction Most patients with breast cancer have early-stage hormone receptor(HR)-positive, human epidermal growth factor receptor-2 (HER2)-negativedisease. Even though the prognosis for most of these patients is good, there isa need to identify patients at risk for poor outcomes and to develop strategiesto mitigate this risk.